Suven gets product patent from India and Japan
16 COMPANY NEWS l BioSpectrum | November 2017 | www . biospectrumindia . com
Intas Pharma slashes cancer drug prices
Suven gets product patent from India and Japan
Drug firm Suven Life Sciences has been granted a patent each by India and Japan for a drug used in the treatment of neurodegenerative diseases .
Suven has been granted one product patent from India and one product patent from Japan corresponding to the New Chemical Entities ( NCEs ) for the treatment of disorders associated with neurodegenerative diseases . The patents are valid till 2027 and 2032 , respectively .
The granted claims of the patents are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer ’ s disease , attention deficient hyperactivity disorder ( ADHD ), Huntington ’ s disease , Parkinson ’ s and Schizophrenia .
The company is very pleased by the grant of these patents for the pipeline of molecules in CNS ( central nervous system ) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally .
Intas Pharmaceuticals Ltd has announced that it will cut down the prices of Bevacizumab drug by 60 per cent . The company states that it will bring relief to a large number of cancer patients in India for whom the drug was out of reach until now .
The Intas Pharma therapy is now priced at Rs 39,995 for the dose strength of 400 mg variant , which makes it 60 per cent less than the currently available options worth about Rs one lakh . Every year over seven lakh patients die due to various types of cancer in India .
Natco Pharma plans API expansion with more investment
Hyderabad-based Natco Pharma is planning to expand its Active Pharmaceutical Ingredient ( API ) and intermediates manufacturing facility in Tamil Nadu . The company is looking at investing in its existing facility , in Thiruvallur District .
The company would be investing around Rs 100 crore in addition to the existing investment of Rs 86.82 crore in the facility to manufacture 16 campaign products at a time , out of 42 API products and R & D activity , with a production capacity of 66.32 tons per annum from existing production capacity of 46.267 tons per annum . The proposed expansion is in a total land span
Bevacizumab slows down the growth of new blood vessels and is used in treating multiple cancers like colorectal , ovarian , cervical , lung and recurrent glioblastoma ( a type of brain tumour ). The drug has been available in India since 2004 but the cost was prohibitive to most patients . Intas Pharma has been growing at a 27 per cent CAGR over the last five years with an even stronger profit growth . Ranked No 10 in the domestic market , the company is one of the top five in the Indian chronic therapy category .
across 10.57 hectares , which is in possession of the company .
The proposed expansion is expected to bring the total jobs in the plant , including existing staff , to 350 direct and 100 indirect jobs . The proposed products will be manufactured on the basis of proven technologies from in-house R & D and private consultants for the cost-effective and environmentally friendly practices , it added . The company has two API manufacturing facilities , one in Mekaguda village , Rangareddy District , Telangana and the other in Manali , Tamil Nadu . The Manali plant is manufacturing various cytotoxic APIs and biotechnology-based products .